Fluctuation of latent inhibition along the estrous cycle in the rat: Modeling the cyclicity of symptoms in schizophrenic women?

Psychoneuroendocrinology

Volumn 33, Issue 10, 2008, Pages 1401-1410

  Arad, Michal ^a   Weiner, Ina ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antipsychotic drugs; Attention; Estrous cycle; Latent inhibition; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; ESTRUS CYCLE; FEMALE; LATENT INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; VAGINA SMEAR;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; CLOZAPINE; CONDITIONING (PSYCHOLOGY); DATA INTERPRETATION, STATISTICAL; EMOTIONS; ESTROUS CYCLE; FEMALE; HALOPERIDOL; RATS; RATS, WISTAR; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VAGINA;

EID: 56249095778     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2008.08.001     Document Type: Article

References (89)

1. Barak S., and Weiner I. Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor. Neuropsychopharmacology 32 (2007) 989-999
2. Baruch I., Hemsley D.R., and Gray J.A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J. Nerv. Ment. Dis. 176 (1988) 598-606
3. Becker J.B., Robinson T.E., and Lorenz K.A. Sex differences and estrous cycle variations in amphetamine-elicited rotational behavior. Eur. J. Pharmacol. 80 (1982) 65-72
4. Becker J.B., Snyder P.J., Miller M.M., Westgate S.A., and Jenuwine M.J. The influence of estrous cycle and intrastriatal estradiol on sensorimotor performance in the female rat. Pharmacol. Biochem. Behav. 27 (1987) 53-59
5. Becker J.B., and Cha J.H. Estrous cycle-dependent variation in amphetamine-induced behaviors and striatal dopamine release assessed with microdialysis. Behav. Brain Res. 35 (1989) 117-125
6. Becker J.B. Direct effect of 17 beta-estradiol on striatum: sex differences in dopamine release. Synapse 5 (1990) 157-164
7. Becker J.B. Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol. Biochem. Behav. 64 (1999) 803-812
8. Bergemann N., Parzer P., Runnebaum B., Resch F., and Mundt C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol. Med. 37 (2007) 1427-1436
9. Caldarone B.J., Duman C.H., and Picciotto M.R. Fear conditioning and latent inhibition in mice lacking the high affinity subclass of nicotinic acetylcholine receptors in the brain. Neuropharmacology 39 (2000) 2779-2784
10. Chang S.S., and Renshaw D.C. Psychosis and pregnancy. Compr. Ther. 12 (1986) 36-41
11. Chang T., Meyer U., Feldon J., and Yee B.K. Disruption of the US pre-exposure effect and latent inhibition in two-way active avoidance by systemic amphetamine in C57BL/6 mice. Psychopharmacology (Berl.) 191 (2007) 211-221
12. Chen J., Lipska B.K., and Weinberger D.R. Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. Biol. Psychiatry 59 (2006) 1180-1188
13. Clapcote S.J., Lipina T.V., Millar J.K., Mackie S., Christie S., Ogawa F., Lerch J.P., Trimble K., Uchiyama M., Sakuraba Y., Kaneda H., Shiroishi T., Houslay M.D., Henkelman R.M., Sled J.G., Gondo Y., Porteous D.J., and Roder J.C. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54 (2007) 387-402
14. Coutureau E., Galani R., Gosselin O., Majchrzak M., and Di Scala G. Entorhinal but not hippocampal or subicular lesions disrupt latent inhibition in rats. Neurobiol. Learn. Mem. 72 (1999) 143-157
15. de Leon J., Diaz F.J., Josiassen R.C., and Simpson G.M. Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment. Eur. Arch. Psychiatry Clin. Neurosci. 254 (2004) 318-325
16. Dickson R.A., Seeman M.V., and Corenblum B. Hormonal side effects in women: typical versus atypical antipsychotic treatment. J. Clin. Psychiatry 61 Suppl. 3 (2000) 10-15
17. Feldon J., and Weiner I. The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biol. Psychiatry 29 (1991) 635-646
18. Fell M.J., Neill J.C., and Marshall K.M. Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats. Eur. Neuropsychopharmacol. 14 (2004) 385-392
19. Gattaz W.F., Vogel P., Riecher-Rossler A., and Soddu G. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biol. Psychiatry 36 (1994) 137-139
20. Gosselin G., Oberling P., and Di Scala G. Antagonism of amphetamine-induced disruption of latent inhibition by the atypical antipsychotic olanzapine in rats. Behav. Pharmacol. 7 (1996) 820-826
21. Gray N.S., Hemsley D.R., and Gray J.A. Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol. Psychiatr. Brain Res. 1 (1992) 83-89
22. Gray N.S., Pickering A.D., Hemsley D.R., Dawling S., and Gray J.A. Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology (Berl.) 107 (1992) 425-430
23. Gray N.S., Pilowsky L.S., Gray J.A., and Kerwin R.W. Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr. Res. 17 (1995) 95-107
24. Gregory B.A. The menstrual cycle and its disorders in psychiatric patients. II. J. Psychosom. Res. 2 (1957) 199-224
25. Grigoriadis S., and Seeman M.V. The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can. J. Psychiatry 47 (2002) 437-442
26. Haddad P.M., and Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64 (2004) 2291-2314
27. Hafner H., Riecher A., Maurer K., Loffler W., Munk-Jorgensen P., and Stromgren E. How does gender influence age at first hospitalization for schizophrenia? A transnational case register study. Psychol. Med. 19 (1989) 903-918
28. Hallonquist J.D., Seeman M.V., Lang M., and Rector N.A. Variation in symptom severity over the menstrual cycle of schizophrenics. Biol. Psychiatry 33 (1993) 207-209
29. Hendrick V., Altshuler L.L., and Burt V.K. Course of psychiatric disorders across the menstrual cycle. Harv. Rev. Psychiatry 4 (1996) 200-207
30. Hietala J., Syvalahti E., Vilkman H., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., Solin O., Kuoppamaki M., Eronen E., Ruotsalainen U., and Salokangas R.K. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr. Res. 35 (1999) 41-50
31. Horacek J., Bubenikova-Valesova V., Kopecek M., Palenicek T., Dockery C., Mohr P., and Hoschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20 (2006) 389-409
32. Huber T.J., Rollnik J., Wilhelms J., von zur Muhlen A., Emrich H.M., and Schneider U. Estradiol levels in psychotic disorders. Psychoneuroendocrinology 26 (2001) 27-35
33. Jans L.A., Lieben C.K., and Blokland A. Influence of sex and estrous cycle on the effects of acute tryptophan depletion induced by a gelatin-based mixture in adult Wistar rats. Neuroscience 147 (2007) 304-317
34. Jori A., and Cecchetti G. Homovanillic acid levels in rat striatum during the oestrous cycle. J. Endocrinol. 58 (1973) 341-342
35. Kendell R.E., Chalmers J.C., and Platz C. Epidemiology of puerperal psychoses. Br. J. Psychiatry 150 (1987) 662-673
36. Killcross A.S., and Robbins T.W. Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm. Psychopharmacology (Berl.) 110 (1993) 479-489
37. Killcross A.S., Dickinson A., and Robbins T.W. Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions. Psychopharmacology (Berl.) 115 (1994) 196-205
38. Killcross A.S., Dickinson A., and Robbins T.W. Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction. Psychopharmacology (Berl.) 115 (1994) 185-195
39. Kinkead B., Yan F., Owens M.J., and Nemeroff C.B. Endogenous neurotensin is involved in estrous cycle related alterations in prepulse inhibition of the acoustic startle reflex in female rats. Psychoneuroendocrinology 33 (2008) 178-187
40. Koch M. Sensorimotor gating changes across the estrous cycle in female rats. Physiol. Behav. 64 (1998) 625-628
41. Kulkarni J., de Castella A., Smith D., Taffe J., Keks N., and Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr. Res. 20 (1996) 247-252
42. Kulkarni J., Gurvich C., Gilbert H., Mehmedbegovic F., Mu L., Marston N., Gavrilidis E., and de Castella A. Hormone modulation: a novel therapeutic approach for women with severe mental illness. Aust. NZ J. Psychiatry 42 (2008) 83-88
43. Kumari V., Cotter P.A., Mulligan O.F., Checkley S.A., Gray N.S., Hemsley D.R., Thornton J.C., Corr P.J., Toone B.K., and Gray J.A. Effects of d-amphetamine and haloperidol on latent inhibition in healthy male volunteers. J. Psychopharmacol. 13 (1999) 398-405
44. Lipina T., Weiss K., and Roder J. The ampakine CX546 restores the prepulse inhibition and latent inhibition deficits in mGluR5-deficient mice. Neuropsychopharmacology 32 (2007) 745-756
45. Lipska B.K., and Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23 (2000) 223-239
46. Lipska B.K. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J. Psychiatry Neurosci. 29 (2004) 282-286
47. Lovick T.A. Plasticity of GABAA receptor subunit expression during the oestrous cycle of the rat: implications for premenstrual syndrome in women. Exp. Physiol. 91 (2006) 655-660
48. Lubow R.E., Weiner I., and Schnur P. Conditioned attention theory. In: Bower G.H. (Ed). The Psychology of Learning and Motivation vol. 15 (1981), Academic Press, New York 1-49
49. Lubow R.E. Latent Inhibition and Conditioned Attention Theory (1989), Cambridge University Press, New York
50. Luggin R., Bernsted L., Petersson B., and Jacobsen A.T. Acute psychiatric admission related to the menstrual cycle. Acta. Psychiatr. Scand. 69 (1984) 461-465
51. Marcondes F.K., Bianchi F.J., and Tanno A.P. Determination of the estrous cycle phases of rats: some helpful considerations. Braz. J. Biol. 62 (2002) 609-614
52. Meyer U., Chang D.L., Feldon J., and Yee B.K. Expression of the CS- and US-pre-exposure effects in the conditioned taste aversion paradigm and their abolition following systemic amphetamine treatment in C57BL6/J mice. Neuropsychopharmacology 29 (2004) 2140-2148
53. Meyer U., Feldon J., Schedlowski M., and Yee B.K. Immunological stress at the maternal-foetal interface: a link between neurodevelopment and adult psychopathology. Brain Behav. Immun. 20 (2006) 378-388
54. Meyer U., Schwendener S., Feldon J., and Yee B.K. Prenatal and postnatal maternal contributions in the infection model of schizophrenia. Exp. Brain Res. 173 (2006) 243-257
55. Miyakawa T., Leiter L.M., Gerber D.J., Gainetdinov R.R., Sotnikova T.D., Zeng H., Caron M.G., and Tonegawa S. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 8987-8992
56. Moran P.M., Fischer T.R., Hitchcock J.M., and Moser P.C. Effects of clozapine on latent inhibition in the rat. Behav. Pharmacol. 7 (1996) 42-48
57. Opjordsmoen S. Long-term clinical outcome of schizophrenia with special reference to gender differences. Acta. Psychiatr. Scand. 83 (1991) 307-313
58. Rascle C., Mazas O., Vaiva G., Tournant M., Raybois O., Goudemand M., and Thomas P. Clinical features of latent inhibition in schizophrenia. Schizophr. Res. 51 (2001) 149-161
59. Riecher-Rossler A., Hafner H., Stumbaum M., Maurer K., and Schmidt R. Can estradiol modulate schizophrenic symptomatology?. Schizophr. Bull. 20 (1994) 203-214
60. Rimer M., Barrett D.W., Maldonado M.A., Vock V.M., and Gonzalez-Lima F. Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition. Neuroreport 16 (2005) 271-275
61. Roberts R.C. Schizophrenia in translation: disrupted in schizophrenia (DISC1): integrating clinical and basic findings. Schizophr. Bull. 33 (2007) 11-15
62. Robinson T.E., Camp D.M., Jacknow D.S., and Becker J.B. Sex differences and estrous cycle dependent variation in rotational behavior elicited by electrical stimulation of the mesostriatal dopamine system. Behav. Brain Res. 6 (1982) 273-287
63. Russig H., Kovacevic A., Murphy C.A., and Feldon J. Haloperidol and clozapine antagonise amphetamine-induced disruption of latent inhibition of conditioned taste aversion. Psychopharmacology (Berl.) 170 (2003) 263-270
64. Salgado J.V., Hetem L.A., Vidal M., Graeff F.G., Danion J.M., and Sandner G. Reduction of latent inhibition by d-amphetamine in a conditioned suppression paradigm in humans. Behav. Brain Res. 117 (2000) 61-67
65. Saugstad L.F. Social class, marriage, and fertility in schizophrenia. Schizophr. Bull. 15 (1989) 9-43
66. Seeman M.V. Prenatal gonadal hormones and schizophrenia in men and women. Psychiatr. J. Univ. Ott. 14 (1989) 473-475
67. Seeman M.V., and Lang M. The role of estrogens in schizophrenia gender differences. Schizophr. Bull. 16 (1990) 185-194
68. Seeman M.V. The role of estrogen in schizophrenia. J. Psychiatry Neurosci. 21 (1996) 123-127
69. Shadach E., Feldon J., and Weiner I. Clozapine-induced potentiation of latent inhibition is due to its action in the conditioning stage: implications for the mechanism of action of antipsychotic drugs. Int. J. Neuropsychopharmacol. 2 (1999) 283-291
70. Shadach E., Gaisler I., Schiller D., and Weiner I. The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin. Neuropsychopharmacology 23 (2000) 151-161
71. Smith S.E., Li J., Garbett K., Mirnics K., and Patterson P.H. Maternal immune activation alters fetal brain development through interleukin-6. J. Neurosci. 27 (2007) 10695-10702
72. Stone J.M., and Pilowsky L.S. Antipsychotic drug action: targets for drug discovery with neurochemical imaging. Expert Rev. Neurother. 6 (2006) 57-64
73. Swerdlow N.R., Stephany N., Wasserman L.C., Talledo J., Sharp R., and Auerbach P.P. Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm. Psychopharmacology (Berl.) 169 (2003) 314-320
74. Swerdlow N.R., Stephany N., Wasserman L.C., Talledo J., Sharp R., Minassian A., and Auerbach P.P. Intact visual latent inhibition in schizophrenia patients in a within-subject paradigm. Schizophr. Res. 72 (2005) 169-183
75. Thornton J.C., Dawe S., Lee C., Capstick C., Corr P.J., Cotter P., Frangou S., Gray N.S., Russell M.A., and Gray J.A. Effects of nicotine and amphetamine on latent inhibition in human subjects. Psychopharmacology (Berl.) 127 (1996) 164-173
76. Tinkler G.P., and Voytko M.L. Estrogen modulates cognitive and cholinergic processes in surgically menopausal monkeys. Prog. Neuropsychopharmacol. Biol. Psychiatry 29 (2005) 423-431
77. Van den Buuse M., Garner B., and Koch M. Neurodevelopmental animal models of schizophrenia: effects on prepulse inhibition. Curr. Mol. Med. 3 (2003) 459-471
78. Warburton E.C., Joseph M.H., Feldon J., Weiner I., and Gray J.A. Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology (Berl.) 114 (1994) 657-664
79. Weiner I., Lubow R.E., and Feldon J. Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology (Berl.) 83 (1984) 194-199
80. Weiner I., Lubow R.E., and Feldon J. Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol. Biochem. Behav. 30 (1988) 871-878
81. Weiner I. Neural substrates of latent inhibition: the switching model. Psychol. Bull. 108 (1990) 442-461
82. Weiner I., Gal G., Rawlins J.N., and Feldon J. Differential involvement of the shell and core subterritories of the nucleus accumbens in latent inhibition and amphetamine-induced activity. Behav. Brain Res. 81 (1996) 123-133
83. Weiner I., Shadach E., Tarrasch R., Kidron R., and Feldon J. The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine. Biol. Psychiatry 40 (1996) 834-843
84. Weiner I. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl.) 169 (2003) 257-297
85. Woolley C.S., and Schwartzkroin P.A. Hormonal effects on the brain. Epilepsia 39 Suppl. 8 (1998) S2-S8
86. Xiao L., and Becker J.B. Quantitative microdialysis determination of extracellular striatal dopamine concentration in male and female rats: effects of estrous cycle and gonadectomy. Neurosci. Lett. 180 (1994) 155-158
87. Yee B.K., Feldon J., and Rawlins J.N. Latent inhibition in rats is abolished by NMDA-induced neuronal loss in the retrohippocampal region, but this lesion effect can be prevented by systemic haloperidol treatment. Behav. Neurosci. 109 (1995) 227-240
88. Yee B.K., Balic E., Singer P., Schwerdel C., Grampp T., Gabernet L., Knuesel I., Benke D., Feldon J., Mohler H., and Boison D. Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. J. Neurosci. 26 (2006) 3169-3181
89. Zuckerman L., Rehavi M., Nachman R., and Weiner I. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology 28 (2003) 1778-1789